Abstract Topics
Research in the following categories is presented at the Annual Meeting


When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract:

A1 – RNA Virus Vectors
A2 – AAV Vectors – Virology and Vectorology
A3 – AAV Vectors – Preclinical and Proof-of-Concept Studies
A4 – AAV Vectors – Clinical Studies

B – Gene Targeting and Gene Correction (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.)
C – Oligonucleotide Therapeutics (siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
D – Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics (Including exosomes)
E1 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
E2 – Cardiovascular and Pulmonary Diseases
E3 – Neurologic Diseases 
E4 – Ophthalmic and Auditory Diseases
E5 – Musculo-skeletal Diseases
E6 – 
Cancer – Immunotherapy, Cancer Vaccines
E7 – Cancer – Oncolytic Viruses
E8 – Cancer – Targeted Gene and Cell Therapy
E9 – Hematologic and Immunologic Diseases

F – Immunological Aspects of Gene Therapy and Vaccines (Includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)
G – Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)
H1 – Vector Product Engineering, Development, or Manufacturing
H2 – Cell Therapy Product Engineering, Development, and Manufacturing
H3 – Pharmacology/Toxicology Studies or Assay Development
I – Gene & Cell Therapy Trials in Progress

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.